Immune Checkpoint Inhibitors in NSCLC
Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the variety of immune checkpoint inhibitors that are currently being explored as treatments for patients with non-small cell lung cancer (NSCLC).
Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the variety of immune checkpoint inhibitors that are currently being explored as treatments for patients with non-small cell lung cancer (NSCLC).
Clinical Pearls:
- Several therapies are being explored in NSCLC that target immune checkpoints, including PD-1 inhibitors nivolumab and MK-3475, and the PD-L1 inhibitor MPDL3280A
- Since these agents have been explored primarily in phase I studies, it remains unclear whether targeting PD-1 or PD-L1 is superior
- At this point, it appears that PD-L1 inhibition could result in fewer side effects, like pneumonitis
- Future research in this space will focus on selecting patients, minimizing toxicities, and determining which class of agents is most effective
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
